AJANTPHARM2021-10-012021-12-31in-bse-fin:OneOperatingExpenses01Member AJANTPHARM2021-10-012021-12-31in-bse-fin:FourOperatingExpenses01Member AJANTPHARM2021-10-012021-12-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member AJANTPHARM2021-10-012021-12-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member AJANTPHARM2021-10-012021-12-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member AJANTPHARM2021-10-012021-12-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares AJANTPHARM 2021-04-01 2022-03-31 2022-01-21 INR Crores Third quarter Single segment PHARMACEUTICAL 2021-10-01 2021-12-31 Unaudited Consolidated 8379100000.00 240300000.00 8619400000.00 2010500000.00 272900000.00 -392800000.00 1621900000.00 9500000.00 317200000.00 2470800000.00 6310000000.00 2309400000.00 0.00 2309400000.00 413500000.00 -21900000.00 391600000.00 0.00 1917800000.00 0.00 0.00 0.00 0.00 1917800000.00 -19100000.00 1898700000.00 0.00 0.00 0.00 0.00 173900000.00 2 22.16 22.16 0.00 0.00 22.16 22.16 1. The above consolidated unaudited financial results have been reviewed by Audit Committee and approved by the Board of Directors at their meeting held on 31 January 2022. The statutory auditors have expressed unmodified opinion on the results for the quarter and nine month period ended 31 December 2021. The review report has been filed with the stock exchange and is available on company website. 2. The consolidated unaudited financial results of the Company, its wholly owned subsidiaries and step-down subsidiary (“the Group”) have been prepared as per Ind AS 110 on Consolidated Financial Statements. There is no minority interest. 3. During the quarter Nil Equity shares (previous year 5,500) of Rs. 2 each, fully paid up, were allotted upon exercise of vested options pursuant to the Employee Stock options Scheme 2011, resulting in an increase in the paid-up share capital by Rs. Nil (previous year Rs. 11,000) and securities premium account by Rs. Nil (previous year Rs. 0.58 Crores). 4. On 28 December 2021, Group has announced buy back of its 11,20,000 equity shares, being 1.29% of the total paid up equity share capital at Rs. 2,550 per equity share for an aggregate amount of Rs. 285.60 crores. The buy back is in process and will open on 03 February 2022 and closes on 16 February 2022. 5. The Group continued to take into account the possible impacts of COVID-19 in preparation of the financial statements, including but not limited to its assessment of liquidity and going concern assumption, recoverable values of its financial and non-financial assets, impact on revenues and on costs. The Group has been able to effectively manage the operations till now with appropriate safety precautions, without any significant impact of COVID-19 on the business. The Group will continue to closely monitor future economic conditions to ensure business continuity. 6. The Group operates exclusively in one reportable business segment i.e., Pharmaceuticals . 7. The Financial Results are available for investors at on the company's website www.ajantapharma.com, www.nseindia.com and www.bseindia.com. 8. Previous period figures have been re-grouped / re-classified wherever necessary, to confirm to current period’s classification in order to comply with the requirements of the amended Schedule III to the Companies Act, 2013 effective 01 April 2021. Single segment 2021-04-01 2021-12-31 Unaudited Consolidated 24707000000.00 862000000.00 25569000000.00 5623800000.00 1018800000.00 -713100000.00 4802600000.00 28600000.00 941400000.00 6748800000.00 18450900000.00 7118100000.00 0.00 7118100000.00 1560600000.00 -57200000.00 1503400000.00 0.00 5614700000.00 0.00 0.00 0.00 0.00 5614700000.00 -84900000.00 5529800000.00 0.00 0.00 0.00 0.00 173900000.00 2 64.89 64.88 0.00 0.00 64.89 64.88 Other Expenses 2470800000.00 Other Expenses 6748800000.00